Rajani Sharma – författare

Gallstone Formation, Diagnosis, Treatment, and Prevention describes the current scenario of gallstones and adopted treatment methods. It is a complete reference for researchers introducing new techniques to help prevent extreme treatments such as a cholecystectomy. This reference provides current knowledge and basic challenges of understanding gallstone formation, with all variations of composition, including complications of the treatment process. This content directs researchers to focus on gallstone mechanisms to design and develop new treatment methods. The book provides all possible factors for gallstone formation as well as preventative measures.

Offers treatment methods, including both chemical and herbal methodsPresents mechanisms behind gallstone formation that are important to researchers to determine treatment methods that can prevent cholecystectomyIncludes the latest research on acute pancreatitis, one of the major concerns of gastrointestinal diseaseDiscusses the effects of gallstone as a cancer-causing mechanism

Antimicrobial Resistance in Humans, Animals, and the Environment: One Health Approach examines the global impact of antimicrobial resistance (AMR) with a specific focus on the interconnectedness between animal, human, and environmental health. The book details the origin, evolution and ecology of AMR and its updated epidemiology. It discusses the transmission of antimicrobial resistance between humans, animals, and the environment. It delves into the molecular mechanisms of drug resistance development and epidemiology in human and animal health; the different challenges in treating antimicrobial-resistant infections including rapid diagnosis and the development of new antimicrobial agents; and alternative strategies treating drug-resistant infections. Antimicrobial Resistance in Humans, Animals, and the Environment: One Health Approach is a useful comprehensive resource for researchers, academics postgraduate students, PhD students, early career researchers, and medical scientists in microbiology, infectious diseases, and biotechnology, public health professionals, clinical personnel treating AMR, or policymakers interested in implementing antimicrobial stewardship program in hospitals.Discusses antimicrobial resistance across the microbial kingdoms of bacteria, fungi, viruses, and protozoa and details the molecular mechanisms of resistance development in microbesExamines the link Between the environment, such as climate change, industrialization, and heavy metal pollution, and the rise of resistant microbesOffers alternative strategies to tackling AMR and the treatment of drug-resistant infections

This new book takes an in-depth look at the emerging and prospective field of computational biology and bioinformatics, which possesses the ability to analyze large accumulated biological data collected from sequence analysis of proteins and genes and cell population with an aim to make new predictions pertaining to drug discovery and new biology. The book explains the basic methodology associated with a bioinformatics and computational approach in drug designing. It then goes on to cover the implementation of computational programming, bioinformatics, pharmacophore modeling, biotechnological techniques, and pharmaceutical chemistry in designing drugs. The major advantage of intervention of computer language or programming is to cut down the number of steps and costs in the field of drug designing, reducing the repeating steps and saving time in screening the potent component for drug or vaccine designing.The book describes algorithms used for drug designing and the use of machine learning and AI in drug delivery and disease diagnosis, which are valuable in clinical decision-making. The implementation of robotics in different diseases like stroke, cancer, COVID-19, etc. is also addressed. Topics include machine learning, AI, databases in drug design, molecular docking, bioinformatics tools, target-based drug design, and immunoinformatics, chemoinformatics, and nanoinformatics in drug design. Drug repurposing in drug design in general as well as for specific diseases, including cancer, Alzheimer’s disease, tuberculosis, COVID-19, etc., is also addressed in depth.